OTLK FY2025 EPS Cut by Brookline Capital Management

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Brookline Capital Management cut their FY2025 earnings per share (EPS) estimates for Outlook Therapeutics in a report issued on Wednesday, November 27th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings of ($1.80) per share for the year, down from their prior estimate of ($1.64). The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($3.84) per share. Brookline Capital Management also issued estimates for Outlook Therapeutics’ Q4 2025 earnings at ($0.36) EPS, FY2026 earnings at $0.61 EPS and FY2027 earnings at $1.18 EPS.

Several other equities research analysts have also recently weighed in on the company. Ascendiant Capital Markets reduced their price objective on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. Chardan Capital restated a “buy” rating and issued a $53.00 price target on shares of Outlook Therapeutics in a research report on Friday, August 16th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Outlook Therapeutics in a report on Friday. Finally, BTIG Research reduced their target price on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research note on Friday. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Outlook Therapeutics currently has an average rating of “Buy” and an average price target of $42.34.

Outlook Therapeutics Stock Up 20.6 %

OTLK opened at $2.05 on Monday. The stock’s 50 day moving average price is $5.29 and its two-hundred day moving average price is $6.70. The firm has a market capitalization of $48.50 million, a P/E ratio of -0.19 and a beta of 0.62. Outlook Therapeutics has a 12-month low of $0.87 and a 12-month high of $12.85.

Institutional Investors Weigh In On Outlook Therapeutics

Large investors have recently modified their holdings of the stock. Great Point Partners LLC lifted its position in shares of Outlook Therapeutics by 15.0% during the 2nd quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock worth $12,557,000 after buying an additional 221,510 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in shares of Outlook Therapeutics during the second quarter valued at $303,000. Squarepoint Ops LLC bought a new position in shares of Outlook Therapeutics during the second quarter valued at $232,000. Christensen King & Associates Investment Services Inc. acquired a new stake in shares of Outlook Therapeutics in the 3rd quarter valued at $55,000. Finally, AQR Capital Management LLC bought a new stake in shares of Outlook Therapeutics in the 2nd quarter worth about $75,000. 11.20% of the stock is currently owned by institutional investors.

Insider Activity

In other Outlook Therapeutics news, CFO Lawrence A. Kenyon purchased 5,000 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was purchased at an average price of $5.69 per share, with a total value of $28,450.00. Following the completion of the transaction, the chief financial officer now directly owns 5,946 shares of the company’s stock, valued at approximately $33,832.74. This trade represents a 528.54 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 3.40% of the stock is owned by company insiders.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.